Lilly reassures investors that weight-loss drug demand is strong, shares rise
Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...
Eli Lilly beats on earnings even as weight loss, diabetes drug sales fall short
Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...
‘Weight-loss jabs have killed my appetite for alcohol’
As the ‘miracle’ drugs sweep the globe, pubs, bars and drinks manufacturers are scrambling to cope with an unexpected side ...
Whoopi Goldberg Slams Weight Loss Drug for Using AI Version of Her Face: “Do Not Look at This”
Goldberg said the company "melded" a CBS News Sunday Mornings appearance from her to sell “bad weight loss drugs." ...
Lilly’s Mounjaro and Zepbound contribute to big revenue boost, drugmaker says
Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.
Inventory issues hobble Lilly sales
Despite heavy demand for its weight-loss and diabetes treatments, limited supply hobbled Eli Lilly's fourth-quarter sales.
Gillingham charity boss hails weight-loss injections including Ozempic, Wegovy and Mounjaro as life-changing after dropping 6st in two months
A charity boss who once tipped the scales at more than 28st says weight-loss injections have changed the way he thinks about ...
RTE Online6h
Eli Lilly forecasts 2025 profit growth after recent weight-loss drug worries
Eli Lilly has today forecast annual profit largely above Wall Street estimates, providing some relief to investors after ...
Exercise and the hidden pitfall of using weight loss jabs
If you’re in a calorie deficit – either from dieting or while taking a weight loss drug – these exercises help direct your ...
Why did Eli Lilly report mixed Q4 results despite soaring demand for Zepbound and Mounjaro?
Eli Lilly reported mixed fourth-quarter results on Thursday, surpassing earnings expectations but falling short of sales projections, even as demand for its flagship weight loss drug Zepbound and ...